This announcement is a separate document:
迈普医学：华泰联合证券有限责任公司关于广州迈普再生医学科技股份有限公司2024年半年度持续督导跟踪报告
Medprin Regenerative Medical Technologies: Huatai United Securities Co., Ltd.'s continuous supervision and follow-up report on the first half of 2024 for Guangzhou Mike Bio-Regenerative Medical Technology Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.